Advent Life Sciences — 2017 Investments
1 investments dated 2017 · listed companies and verified rows first · show all
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)Mark DeLong(CEO)David Neafus(Executive Officer)Russell C. Petter(Executive Officer)
BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in
Board seatRaj ParekhAlan Walts· per SEC Form D
Co-investorsCanaan PartnersPfizer VenturesNextech InvestOUP (Osage University Partners)Pfizer Venture InvestmentsvenBio Partners+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.